

EXECUTIVE AGENCY
FISCAL NOTE

AGENCY'S ESTIMATES

Date Prepared: March 3, 2023

Agency Submitting: Department of Health and Human Services, Health Care Financing and Policy

| Items of Revenue or Expense, or Both | Fiscal Year 2022-23 | Fiscal Year 2023-24 | Fiscal Year 2024-25 | Effect on Future Biennia |
|---|----------------------------|----------------------------|----------------------------|---------------------------------|
| | | | | |
| Total | 0 | 0 | 0 | 0 |

Explanation

(Use Additional Sheets of Attachments, if required)

The Division has reviewed this BDR and determined that there is no projected financial impact. Fee-for-Service Medicaid and three of the four Managed Care Organizations do not utilize step therapy for the classes of drugs impacted by this bill. One Managed Care Organization does use step therapy to manage utilization of one drug (Olanzapine) but confirmed there is no anticipated fiscal impact tied to this BDR.

Name Stacie Weeks

Title Administrator

GOVERNOR'S OFFICE OF FINANCE COMMENTS

Date Wednesday, March 01, 2023

The agency's response appears reasonable.

Name Amy Stephenson

Title Director